Clinical Trials Browser

Phase 2/3 × INDUSTRY × sitravatinib × Clear all

NCT04887870 2025-10-10

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Phase 2/3 Completed

Advanced or Metastatic Solid Malignancies